648905-80-0Relevant articles and documents
A selective estrogen receptor modulator designed for the treatment of uterine leiomyoma with unique tissue specificity for uterus and ovaries in rats
Hummel, Conrad W.,Geiser, Andrew G.,Bryant, Henry U.,Cohen, Ilene R.,Dally, Robert D.,Fong, Kin Chiu,Frank, Scott A.,Hinklin, Ronald,Jones, Scott A.,Lewis, George,McCann, Denis J.,Rudmann, Daniel G.,Shepherd, Timothy A.,Tian, Hongqi,Wallace, Owen B.,Wang, Minmin,Wang, Yong,Dodge, Jeffrey A.
, p. 6772 - 6775 (2005)
The design of a novel selective estrogen receptor modulator (SERM) for the potential treatment of uterine leiomyoma is described. 16 (LY2066948-HCl) binds with high affinity to estrogen receptors α and β (ERα and ERβ, respectively) and is a potent uterine
SELECTIVE ESTROGEN RECEPTOR MODULATORS
-
Page/Page column 47-48, (2010/02/13)
The present invention relates to a selective estrogen receptor modulators of formula I (I); or a pharmaceutical acid addition salt thereof; and of formula II (II); or a pharmaceutical salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
DERIVATIVE OF DIHYDRO-DIBENZO (A) ANTHRACENES AND THEIR USE AS SELECTIVE ESTROGEN RECEPTOR MODULATORS
-
Page 23, (2008/06/13)
The present invention provides a compound of the formula (I) wherein R1 is -H, -OH, -O(C1-C4 alkyl), -OCOC6H5, -OCO(C1-C6 alkyl), or -OSO2(C2-C6